Found: 70
Select item for more details and to access through your institution.
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 4, p. 784, doi. 10.1111/bjh.17541
- By:
- Publication type:
- Article
Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 1, p. 132, doi. 10.1111/bjh.17435
- By:
- Publication type:
- Article
A five‐year follow‐up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial.
- Published in:
- British Journal of Haematology, 2020, v. 190, n. 5, p. 736, doi. 10.1111/bjh.16625
- By:
- Publication type:
- Article
Five‐year survival follow‐up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine‐refractory chronic lymphocytic leukaemia: a short report.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 4, p. 689, doi. 10.1111/bjh.16429
- By:
- Publication type:
- Article
Phase 2 study of all‐oral ixazomib, cyclophosphamide and low‐dose dexamethasone for relapsed/refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2019, v. 184, n. 4, p. 536, doi. 10.1111/bjh.15679
- By:
- Publication type:
- Article
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
- Published in:
- British Journal of Haematology, 2017, v. 178, n. 6, p. 896, doi. 10.1111/bjh.14787
- By:
- Publication type:
- Article
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.
- Published in:
- British Journal of Haematology, 2016, v. 175, n. 5, p. 884, doi. 10.1111/bjh.14328
- By:
- Publication type:
- Article
Mass/heat transfer analogy method in the research of convective fluid flow through channels with a specific geometry.
- Published in:
- Archives of Thermodynamics, 2023, v. 44, n. 4, p. 427, doi. 10.24425/ather.2023.149722
- By:
- Publication type:
- Article
Donor's age influences outcome in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide - a single center experience.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 8, p. 3095, doi. 10.1007/s00277-024-05848-z
- By:
- Publication type:
- Article
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 7, p. 2299, doi. 10.1007/s00277-024-05665-4
- By:
- Publication type:
- Article
Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study.
- Published in:
- Annals of Hematology, 2017, v. 96, n. 10, p. 1693, doi. 10.1007/s00277-017-3084-9
- By:
- Publication type:
- Article
Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Diagnosis and treatment of immune thrombocytopenia in Poland.
- Published in:
- Hematology in Clinical Practice, 2022, v. 13, n. 2, p. 49, doi. 10.5603/HCP.a2022.0013
- By:
- Publication type:
- Article
Polish Experts' Position Statement on the use of granulocyte colony-stimulating factor in the treatment of chronic lymphocytic leukemia with venetoclax combined with rituximab.
- Published in:
- Hematology in Clinical Practice, 2021, v. 33, n. 2, p. 67, doi. 10.5603/HCP.2021.0008
- By:
- Publication type:
- Article
The importance of antiangiogenic effect in multiple myeloma treatment.
- Published in:
- Advances in Clinical & Experimental Medicine, 2018, v. 27, n. 2, p. 291, doi. 10.17219/acem/68826
- By:
- Publication type:
- Article
Recommendations for the diagnosis and treatment of patients with polycythaemia vera.
- Published in:
- European Journal of Haematology, 2018, v. 101, n. 5, p. 654, doi. 10.1111/ejh.13156
- By:
- Publication type:
- Article
Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma.
- Published in:
- European Journal of Haematology, 2013, v. 91, n. 2, p. 122, doi. 10.1111/ejh.12144
- By:
- Publication type:
- Article
Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group
- Published in:
- European Journal of Haematology, 2008, v. 80, n. 2, p. 115, doi. 10.1111/j.1600-0609.2007.00988.x
- By:
- Publication type:
- Article
The results of imatinib therapy for patients with primary eosinophilic disorders.
- Published in:
- 2006
- By:
- Publication type:
- Letter
Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies.
- Published in:
- Trials, 2023, v. 24, n. 1, p. 1, doi. 10.1186/s13063-022-06982-7
- By:
- Publication type:
- Article
Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies.
- Published in:
- Trials, 2023, v. 24, n. 1, p. 1, doi. 10.1186/s13063-022-06982-7
- By:
- Publication type:
- Article
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 12, p. 917, doi. 10.1016/j.clml.2023.08.018
- By:
- Publication type:
- Article
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 9, p. e286, doi. 10.1016/j.clml.2023.06.001
- By:
- Publication type:
- Article
Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 7, p. 491, doi. 10.1016/j.clml.2023.03.007
- By:
- Publication type:
- Article
Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Single-Centre Experience.
- Published in:
- 2023
- By:
- Publication type:
- journal article
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 11, p. 785, doi. 10.1016/j.clml.2021.06.005
- By:
- Publication type:
- Article
P-210: Oral ixazomib (Ixa), IV daratumumab (Dara), and dexamethasone (dex; IDd) in relapsed/refractory multiple myeloma (RRMM) patients (pts) with 1–3 prior therapies: phase 2 study interim analysis (IA).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S154, doi. 10.1016/S2152-2650(21)02337-5
- By:
- Publication type:
- Article
P-193: Elotuzumab plus pomalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT-3 trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S143, doi. 10.1016/S2152-2650(21)02320-X
- By:
- Publication type:
- Article
IBCL-203: Umbralisib, a PI3Kδ/CK1ε Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S404, doi. 10.1016/S2152-2650(21)01912-1
- By:
- Publication type:
- Article
MPN-106: Improved Transfusion Independence Rates for Momelotinib vs Ruxolitinib in Anemic JAKi-Naïve Myelofibrosis Patients are Independent of Baseline Platelet or Transfusion Status.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S353, doi. 10.1016/S2152-2650(21)01817-6
- By:
- Publication type:
- Article
CLL-045: Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S316, doi. 10.1016/S2152-2650(21)01747-X
- By:
- Publication type:
- Article
Poster: IBCL-203: Umbralisib, a PI3Kδ/CK1ε Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S244, doi. 10.1016/S2152-2650(21)01537-8
- By:
- Publication type:
- Article
Poster: MPN-106: Improved Transfusion Independence Rates for Momelotinib vs Ruxolitinib in Anemic JAKi-Naïve Myelofibrosis Patients are Independent of Baseline Platelet or Transfusion Status.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S231, doi. 10.1016/S2152-2650(21)01453-1
- By:
- Publication type:
- Article
Poster: CLL-045: Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S221, doi. 10.1016/S2152-2650(21)01393-8
- By:
- Publication type:
- Article
Elotuzumab, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Efficacy After Additional Follow-Up of the ELOQUENT-3 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e164, doi. 10.1016/j.clml.2019.09.275
- By:
- Publication type:
- Article
Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e15, doi. 10.1016/j.clml.2019.09.022
- By:
- Publication type:
- Article
Five-Year Follow-Up After Ibrutinib Therapy for First-Line Treatment of Chronic Lymphocytic Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S274, doi. 10.1016/j.clml.2019.07.205
- By:
- Publication type:
- Article
Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S253, doi. 10.1016/j.clml.2018.07.155
- By:
- Publication type:
- Article
An Open-label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib, Cyclophosphamide, and Dexamethasone (ICd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S333, doi. 10.1016/j.clml.2017.07.148
- By:
- Publication type:
- Article
Exome Sequencing of AL Amyloidosis Reveals Recurrently Mutated Genes.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e41, doi. 10.1016/j.clml.2017.03.073
- By:
- Publication type:
- Article
Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e131, doi. 10.1016/j.clml.2017.03.237
- By:
- Publication type:
- Article
Phase 3 Study of Ibrutinib versus Chlorambucil in Patients ≥65 Years with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S45, doi. 10.1016/j.clml.2016.07.065
- By:
- Publication type:
- Article
Analysis of Quality of Life and Well-being from the Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Older Patients with Treatment-naïve CLL (RESONATE-2TM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S46, doi. 10.1016/j.clml.2016.07.066
- By:
- Publication type:
- Article
Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome—Polish Adult Leukemia Group (PALG) pilot study.
- Published in:
- Annals of Hematology, 2008, v. 87, n. 5, p. 361, doi. 10.1007/s00277-007-0421-4
- By:
- Publication type:
- Article
SARS-CoV-2 infection in patients with multiple myeloma: survey in 23 centers across Europe and USA.
- Published in:
- Acta Haematologica Polonica, 2023, v. 54, n. 2, p. 82, doi. 10.5603/AHP.a2023.0016
- By:
- Publication type:
- Article
Allogeneic hematopoietic stem cells transplantation for relapsed and refractory acute myeloid leukemia in a single center experience.
- Published in:
- Acta Haematologica Polonica, 2022, v. 53, n. A, p. 73
- By:
- Publication type:
- Article
SEQUOIA: results of a phase 3 randomized study of Zanubrutinib versus Bendamustine + Rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
- Published in:
- Acta Haematologica Polonica, 2022, v. 53, n. A, p. 32
- By:
- Publication type:
- Article
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41408-020-00357-4
- By:
- Publication type:
- Article
Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 12, p. 1, doi. 10.1038/s41408-019-0260-2
- By:
- Publication type:
- Article